H.R. 1660 would require the U.S. Agency for International Development to report annually to the Congress over the 2018-2022 period on the development and use of innovations in the agency’s global health programs. Based on the cost of similar reports, CBO estimates that implementing the bill would cost less than $500,000 over the 2018-2022 period; such spending would be subject to the availability of appropriated funds.
Enacting H.R. 1660 would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply. CBO estimates that enacting H.R. 1660 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2028.
H.R. 1660 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.